The Evidence for Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Neutrophil Disorders: a Comprehensive Review by the Inborn Errors Working Party group of the EBMT.
- 1Division for Stem Cell Transplantation and Immunology, University Hospital Frankfurt, Germany
- 2Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Israel
- 3Department of Immunology, Garvan Institute of Medical Research, Australia
- 4Graduate Research School, University of New South Wales, Australia
Congenital disorders of the immune system affecting maturation and/or function of phagocytic leucocytes can result in severe infectious and inflammatory complications with high mortality and morbidity. Further complications include progression to MDS/AML in some cases. Allogeneic stem cell transplantation is the only curative treatment for most patients with these diseases. In this review, we provide a detailed update on indications and outcomes of alloHSCT for congenital neutrophil disorders, based on data from the available literature.
Keywords: neutrophil disorders alloHSCT, IUIS Classification,, inborn errors, Genetic diseases, Transplantation
Received: 10 Jul 2019;
Accepted: 07 Oct 2019.
Copyright: © 2019 Bakhtiar, Shadur and Stepensky. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Prof. Polina Stepensky, Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Jerusalem, 91120, Jerusalem, Israel, email@example.com